BELLUS Health Inc.
| Company Name | BELLUS Health Inc. |
| Stock Symbol | BLU |
| Class Period | September 05, 2019 to July 05, 2020 |
| Lead Plaintiff Motion Deadline | May 17, 2021 |
BELLUS is a clinical-stage biopharmaceutical company whose lead product is BLU-5937, which is being developed for the treatment of chronic cough and other afferent hypersensitization-related disorders.
On July 6, 2020, before the market opened, BELLUS announced topline results from its Phase 2 RELIEF trial of BLUE-5937 in patients with refractory chronic cough. According to the Company, the trial “did not achieve statistical significance for the primary endpoint of reduction in placebo-adjusted cough frequency at any dose tested.”
On this news, the Company’s stock price fell $9.05, or 75%, over two consecutive trading sessions to close at $2.97 on July 8, 2020, thereby injuring investors.
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, the complaint alleges that Defendants knew, but failed to disclose, that while BLU-5937’s “high selectivity” contributed to the drug causing little to no taste alteration in chronic cough patients, that high selectivity also contributed to the drug potentially being less efficacious and thus likely not be able to meet the primary endpoint of the Company’s Phase 2 trial.
Submit Your Information
If you suffered a loss on your BELLUS Health Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.